logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Osteoporosis

    FiltersReset Filters
    14 results

    • alendronate

      (ALENDRONATE SODIUM)
      Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd.
      Usage: Alendronate sodium tablets are indicated for treating and preventing osteoporosis in postmenopausal women, increasing bone mass in men with osteoporosis, treating glucocorticoid-induced osteoporosis, and treating Paget’s disease of bone. Use should be periodically re-evaluated, particularly for low-risk fracture patients after 3 to 5 years.

    • alendronate

      (Alendronate sodium tablet)
      Marlex Pharmaceuticals Inc
      Usage: Alendronate sodium is indicated for treating osteoporosis in postmenopausal women, increasing bone mass in men with osteoporosis, preventing postmenopausal osteoporosis, treating glucocorticoid-induced osteoporosis, and managing Paget's disease of bone in symptomatic patients or those at risk for complications. Reinforcement of therapy need is recommended periodically.

    • alendronate sodium

      (Alendronate Sodium)
      Hikma Pharmaceuticals USA Inc.
      Usage: Alendronate sodium is indicated for treating osteoporosis in postmenopausal women and increasing bone mass in men with osteoporosis. It helps increase bone mass and reduce fracture incidence, particularly in the hip and spine. Re-evaluations for continued therapy are recommended every few years.

    • estradiol

      (Estradiol)
      Teva Pharmaceuticals USA, Inc.
      Usage: Estradiol tablets are indicated for treating moderate to severe menopause symptoms, vulvar and vaginal atrophy, hypoestrogenism, and for palliation in breast cancer and prostate cancer. They may also be used for preventing osteoporosis in postmenopausal women at significant risk when non-estrogen options are unsuitable.

    • forteo

      (Teriparatide)
      Eli Lilly and Company
      Usage: FORTEO is indicated for treating high-risk postmenopausal women and men with osteoporosis, including those intolerant to other therapies. It also increases bone mass in men with primary or hypogonadal osteoporosis and treats osteoporosis related to long-term glucocorticoid use, reducing fracture risk in these populations.

    • fosamax

      (alendronate sodium)
      Organon LLC
      Usage: FOSAMAX is indicated for treating and preventing osteoporosis in postmenopausal women, increasing bone mass in men with osteoporosis, treating glucocorticoid-induced osteoporosis, and managing Paget's disease of bone. It enhances bone mass and reduces fracture incidence across these conditions. Regular reassessment for continued therapy is recommended.

    • fosamax plus d

      (ALENDRONATE SODIUM and CHOLECALCIFEROL)
      Organon LLC
      Usage: FOSAMAX PLUS D is indicated for treating osteoporosis in postmenopausal women and increasing bone mass in men with osteoporosis. It enhances bone mass and lowers the risk of fractures, but is not for treating vitamin D deficiency. Optimal duration and need for continued therapy must be periodically reassessed.

    • risedronate sodium

      (Risedronate Sodium)
      Greenstone LLC
      Usage: Risedronate Sodium is indicated for treating and preventing postmenopausal osteoporosis, increasing bone mass in men with osteoporosis, and preventing glucocorticoid-induced osteoporosis. It also treats Paget’s disease of bone in both men and women. Optimal duration of therapy has not been established, warranting periodic re-evaluation.

    • risedronate sodium

      (risedronate sodium)
      Sun Pharmaceutical Industries, Inc.
      Usage: Risedronate sodium tablets are indicated for treating and preventing postmenopausal osteoporosis, increasing bone mass in men with osteoporosis, preventing glucocorticoid-induced osteoporosis, and treating Paget's disease of bone. Periodic re-evaluation of treatment necessity is recommended for all patients.

    • risedronate sodium

      (Risedronate Sodium)
      Teva Pharmaceuticals USA, Inc.
      Usage: Risedronate sodium tablets are indicated for the treatment and prevention of postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, and Paget’s disease of bone. Regular evaluation of therapy necessity and fracture risk is recommended for long-term users.